Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 6
Submit an article Journal homepage
325
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Real-world outcomes of frontline venetoclax-based therapy in older adults with acute myeloid leukemia: an analysis utilizing EHR data

Fieke W. Hoffa Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA;b Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USAORCID Iconhttps://orcid.org/0000-0002-7128-1255View further author information
ORCID Icon,
Prapti A. Patela Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA;b Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USAView further author information
,
Andrew J. Bellic COTA, Inc., New York, NY, USAView further author information
,
Eric Hansenc COTA, Inc., New York, NY, USAView further author information
,
Heidi Fossc COTA, Inc., New York, NY, USAView further author information
,
Molly Schultec COTA, Inc., New York, NY, USAView further author information
,
Ching-Kun Wangc COTA, Inc., New York, NY, USAView further author information
&
Yazan F. Madanata Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA;b Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USACorrespondence[email protected]
View further author information
 show all
Pages 1123-1128 | Received 06 Jan 2023, Accepted 20 Mar 2023, Published online: 13 Apr 2023

  • Shallis RM, Wang R, Davidoff A, et al. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70–87.
  • Bazarbachi A. Exciting times ahead for older patients with acute myeloid leukemia: azacitidine and venetoclax followed by allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021;57(2):147–148.
  • DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629.
  • Wei AH, Panayiotidis P, Montesinos P, et al. 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150). Blood Cancer J. 2021;11(10):163.
  • Pollyea DA, Pratz K, Letai A, et al. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow‐up from a phase 1b study. Am J Hematol. Silver Spring, MD, USA 2021;96(2):208–217.
  • DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17.
  • Wei AH, Panayiotidis P, Montesinos P, et al. Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy. Blood. 2022;140(25):2754–2756.
  • Juliusson G, Lazarevic V, Hörstedt A-S, et al. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood. 2012;119(17):3890–3899.
  • Smith BD, Beach CL, Mahmoud D, et al. Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis. Exp Hematol Oncol. 2014;3(1):10.
  • Winters AC, Gutman JA, Purev E, et al. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv. 2019;3(20):2911–2919.
  • Apel A, Moshe Y, Ofran Y, et al. Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice. Am J Hematol. 2021;96(7):790–795.
  • Matthews AH, Perl AE, Luger SM, et al. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Adv. 2022;6(13):3997–4005.
  • Vachhani P, Flahavan EM, Xu T, et al. Venetoclax and hypomethylating agents as first-line treatment in newly diagnosed patients with AML in a predominately community setting in the US. Oncologist. 2022;27(11):907–918.
  • FDA approves venetoclax in combination for AML in adults. Silver Spring, MD; FDA; 2018.
  • Creutzig U, van den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120(16):3187–3205.
  • Bataller A, Garrido A, Guijarro F, et al. European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. Blood Adv. 2022;6(4):1193–1206.
  • Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood Adv. 2017;129(4):424–447.
  • Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137–2145.
  • Wei AH, Strickland, Jr SA, Hou J-Z, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J Clin Oncol. 2019;37(15):1277–1284.
  • Fieke W. Hoff, Prapti A. Patel, Eric Hansen, et al. Agreement between real-world physician response assessment and the 2022 European LeukemiaNet (ELN) criteria in acute myeloid leukemia, 2022.
  • DiNardo C., Tiong I., Quaglieri A, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135(11):791–803.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.